Serum Uric Acid Levels in Patients with Relapsing-Remitting Multiple Sclerosis
Full Text (PDF)
Konca Altınkaynak 1, Asuman Orhan Varoğlu 2 * , Hülya Aksoy 1, Orhan Deniz 2, Asude Aksoy 3
More Detail
1 Department of Biochemistry, Faculty of Medicine, Ataturk University, 25240, Erzurum, Private Hayat Hospital, Elazıg, Turkey.2 Department of Neurology, Faculty of Medicine, Ataturk University, 25240, Erzurum, Private Hayat Hospital, Elazıg, Turkey.3 General Internal Medicine, Ataturk University, 25240, Erzurum, Private Hayat Hospital, Elazıg, Turkey.* Corresponding Author

Abstract

Aim: Multiple sclerosis (MS) is an inflammatory demyelinating disease with unknown origin. Several studies suggest lower levels of serum uric acid (UA), an endogenous antioxidant, in MS patients. Methods: In this study, we aimed to investigate serum UA levels in relapsing-remitting (RR) MS. In addition we compared serum UA levels by means of clinical activity, expanded disability status scale (EDSS) and disease duration. Results: In the present study, mean serum UA levels were lower in RRMS and relapse patients with MS than in the other neurological diseases (OND) group, but the difference did not reach significance level. UA levels did not correlate with clinical activity, EDSS score and disease duration either in relapse or remitting or both of them. Conclusion: In conclusion, this study suggests serum uric acid levels may affect neither pathogenesis of MS nor activity of disease. Further studies are needed to clarify the role of uric acid in MS patients.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Original Article

EUR J GEN MED, Volume 6, Issue 3, July 2009, 166-169

https://doi.org/10.29333/ejgm/82663

Publication date: 15 Jul 2009

Article Views: 1821

Article Downloads: 1076

Open Access References How to cite this article